Abstract
In the present study, we report the uncommon case of a 9.6-yr-old girl with circulating an-ti-T3 autoantibodies (T3-Ab) and hyperthyroidism due to inappropriate secretion of TSH (IST). The diagnosis of IST was based on the findings of normal TSH levels (2.4 mU/L) in the presence of high free T4 (28.2 pmol/L) and free T3 (FT3) levels, as measured by direct measurement methods based on “one-step” analog tracer (28.0 pmo/L) and “two-step” Lisophase® (13.3 pmo/L) techniques. The discrepancy between the two measurements suggested a methodological interference due to T3-Ab in “one-step” technique, being the “two-step” methodology unaffected by the presence of such autoantibodies. T3-Ab were documented by high nonspecific binding of serum to labeled T3 (38.0% vs 4.3 ± 2.1% in controls). The clinical picture of hyperthyroidism, the qualitatively normal TSH responses to TRH and T3 suppression tests, the normal pituitary imaging and the values of some parameters of peripheral thyroid hormone action compatible with hyperthyroidism indicated that the patient was affected by pituitary resistance to thyroid hormones (PRTH). Chronic treatment with dopaminergic agent bromocriptine (7.5 mg/day) did not cause TSH secretion to be suppressed, while the administration of thyroid hormone analog TRIAC (1.4 mg/day) inhibited TSH release (from 2.4 to 0.2 mU/L). As a consequence, circulating thyroid hormone levels normalized and euthyroidism was restored. During TRIAC administration, FT3 levels, measured by “one-step” analog tracer technique, gave spuriously high values due to the methodological interference of T3-Ab (15.2 vs 4.3 pmol/L as measured by “two-step” Lisophase® technique). In conclusion, the present study indicates that a) the levels of circulating free thyroid hormones should be measured by methods unaffected by the presence of anti-iodothyronine autoantibodies in order to prevent either misdiagnosis of IST or, as in the present case, misinterpretation of the efficacy of TSH suppressive treatment, and b) it is mandatory to rule out the presence of such autoantibodies whenever IST is suspected.
References
Gershengorn M.C., Weintraub B.D. Thyrotropin-induced hyperthyroidism caused by selective pituitary resistance to thyroid hormone. A new syndrome of “inappropriate secretion of TSH”. J. Clin. Invest. 56:633, 1975.
Weintraub B.D., Gershengorn M.C., Kourides I.A., Fein H. Inappropriate secretion of thyroid-stimulating hormone. Ann. Intern. Med. 95:339,1981.
Brenner-Gati L, Gershengorn M.C. Thyroid-stimulating hormone-induced hyperthy roidism. In: Imura H. (Ed.), The pituitary gland. Raven Press, New York, 1985, p. 467.
Faglia G., Beck-Peccoz P.V., Piscitelli G., Medri G. Inappropriate secretion of thyrotropin by the pituitary. Horm. Res. 26:79, 1987.
Refetoff S. Syndromes of thyroid hormone resistance. Am. J. Physiol. 243: E88, 1982.
Cooper D.S., Ladenson P.W., Nisula B.C., Dunn J.F., Chapman E.M., Ridgway E.C. Familial thyroid hormone resistance. Metabolism 31: 504, 1982.
Refetoff S., Salazar A., Smith T.J., Scherberg N.V.H. The consequences of inappropriate treatment because of failure to recognize the syndrome of pituitary and peripheral tissue resistance to thyroid hormone. Metabolism 32:822, 1983.
Pagliara A.S., Caplan R.H., Gundersen C.B., Wickus G.G., Elston A.V.C. Peripheral resistance to thyroid hormone in a family: heterogeneity of clinical presentation. J. Pediatr. 703:228,1983.
Pryds O., Hadberg A., Kastrup K.W. Circulating autoantibodies to thyroid hormones: a di agnostic pitfall. Acta Pediatr. Scand. 76: 685, 1987.
Wu S.E., Green W.L. Triiodothyronine (T3)-binding immunoglobulins in a euthyroid woman: effects on measurement of T3(RIA) and on T3 turnover. J. Clin. Endocrinol. Metab. 42:642, 1976.
Ginsberg J., Segal D., Herlich R.M., Walfish P.G. Inappropriate triiodothyronine (T3) and thyroxine (T4) radioimmunoassay levels secondary to circulating thyroid hormone autoantibodies. Clin. Endocrinol. (Oxf.) 8:133, 1978.
Beck-Peccoz P., Romelli P.B., Faglia G. Circulating antitriiodothyronine autoantibodies in two euthyroid patients: apparent lack of interference in total T3 radioimmunoassay based on second anti body or solid phase separation techniques. J. Endocrinol. Invest. 6:333,1983.
Beck-Peccoz P., Romelli P.B., Cattaneo M.G., Faglia G., White E.L., Barlow J.W., Stockigt J.R. Evaluation of free thyroxine methods in the presence of iodothyronine-binding autoantibodies. J. Clin. Endocrinol. Metab. 53:736,1984.
Konishi J., Iida Y., Kuosaka T., Ikekubo K., Nagakawa T., Torizuka K. Effect of anti-thyroxine autoantibodies on radioimmunoassay of free thyroxine in serum. Clin. Chem. 23:1389,1982.
Sakata S., Nakamura S., Miura K. Autoantibodies against thyroid hormones or iodothy- ronine. Implications in diagnosis, thyroid function, treatment and pathogenesis. Ann. Intern. Med. 103:579, 1985.
Beck-Peccoz P., Medri G., Rossi C., Romelli P.B. Circulating antibodies against iodothyronine cause spurious results in specific thyroid hormone immunoassays. J.Clin. Immunoassay 9:211, 1986. 17._EkinsR.P. Free hormones in blood: the concept and the measurement. J. Clin. Immunoassay 7:163,1984.
Greulich W.W., Pyle S. I. Radiographic atlas of skeletal development of the hand and wrist., ed. 2. Stanford University Press, Stanford, 1959.
Romelli P.B., Pennisi F., Vancheri L. Measurement of free thyroid hormones in serum by column adsorption chromatography and radioim munoassay. J. Endocrinol. Invest. 2:25,1979.
Diamandis E.P. Immunoassays with time-resolved fluorescence spectroscopy: principles and applications. Clin. Biochem. 21:139,1988.
Faglia G., Beck-Peccoz P., Ballabio M., Nava C. Excess of β-subunit of thyrotropin (TSH) in patients with idiopathic central hypothyroidism due to the se cretion of TSH with reduced biological activity. J. Clin. Endocrinol. Metab. 56:908, 1983.
Friedman M.J., Okada R.D., Ewy G.A., Hellman D.J. Left ventricular systolic and diastolic function in hy perthyroidism. Am. Heart J. 704:1303, 1982.
Ooi T.C., Whitlock R.M.L., Frengley P.A., Ibbertson H.K. Systolic time intervals and ankle reflex time in patients with minimal serum TSH elevation: response to triiodothyronine therapy. Clin. Endocrinol. (Oxf.) 13: 621,1980.
Beck-Peccoz P., Piscitelli G., Medri G., Ballabio M., Faglia G. Thyroid test strategy. Lancet 7:1456, 1985.
Stockigt J.R., DeGaris M., Csicsmann J., Barlow J.W., White E.L., Hurley D.M. Limitations of a new free thyroxine assay (Amerlex Free T4). Clin. Endocrinol. (Oxf.) 75:313,1981.
Spanheimer R.G., Bar R.S., Hayford J.C. Hyperthyroidism caused by inappropriate thyrotropin hypersecretion: studies in patients with selective pi tuitary resistance to thyroid hormone. Arch. Intern. Med. 742:1283,1982.
Beck-Peccoz P., Mariotti S., Guillausseau P.J., Medri G., Piscitelli G., Berteli A., Barbarino A., Rondena M., Chanson Ph., Pinchera A., Faglia G. Treatment of hyperthyroidism due to inappropriate secretion of thyrotropin with the somatostatin analog SMS 201–995. J. Clin. Endocrinol. Metab. 63:208,1989.
Beck-Peccoz P., Roncoroni R., Mariotti S., Medri G., Marcocci C., Brabant G., Forloni F., Pinchera A., Faglia G. Sex hormone-binding globulin measurement in patients with inappropriate secretion of thyrotropin (1ST): evidence against selective pituitary thyroid hormone resistance in nonneoplastic 1ST. J. Clin. Endocrinol. Metab. 71:19, 1990.
Rosier A., Litvin Y., Hage C., Gross J., Cerasi E. Familial hyperthyroidism due to inappropriate thy rotropin secretion successfully treated with tri iodothyronine. J. Clin. Endocrinol. Metab. 54:76,1982.
Mariotti S., Anelli S., Bartalena L, Bechi R., Martino E., Mammoli C, Beck-Peccoz P., Pinchera A. Familial hyperthyroidism due to nonneoplastic inap propriate TSH secretion associated with sellar ab normalities. J. Endocrinol. Invest. (Suppl.1) 70:20, 1987 (Abstrat).
Beck-Peccoz P., Piscitelli G., Cattaneo M.G., Faglia G. Successful treatment of hyperthyroidism due to non neoplastic pituitary TSH hypersecretion with 3,5,3′-tri- iodothyroacetic acid (TRIAC). J. Endocrinol. Invest. 6:217,1983.
Salmela P.I., Wide L., Juustila H., Ruokonen A. Effects of thyroid hormones (T4, T3), bromocriptine and TRIAC on inappropriate TSH hypersecretion. Clin. Endocrinol. (Oxf) 28:497, 1988.
Langer HJ., Leicht E., Koch B., Eber O. Familiäre, nicht-neoplastische inadäquate Thyreo-tropin-lnkretion. Dtsch. Med. Wschr, 115:813, 1990.
Kunitake J.M., Hartman N., Henson L.C., Lieberman J., Williams D.E., Wong M., Hershman J.M. 3,5,3′-triiodothyroacetic acid therapy for thyroid hor mone resistance. J. Clin. Endocrinol. Metab. 69:46,1989.
Hamon P., Bovier-Lapierre M., Robert M., Peynaud D., Pugeat M., Orgiazzi J. Hyperthyroidism due to selective pituitary resistance to thyroid hormones in a 15-month-old boy: efficacy of D-Thyroxine therapy. J. Clin. Endocrinol. Metab. 67:1089, 1988.
Dorey F., Strauch G., Gayno J.P. Thyrotoxicosis due to pituitary resistance to thyroid hormones. Successful control with D-thyroxine; a study in three patients. Clin. Endocrinol. (Oxf.) 32:221, 1990.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Crinò, A., Borrelli, P., Salvatori, R. et al. Anti-iodothyronine autoantibodies in a girl with hyperthyroidism due to pituitary resistance to thyroid hormones. J Endocrinol Invest 15, 113–120 (1992). https://doi.org/10.1007/BF03348675
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03348675